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study to determine the epidemiology of and mortality associated
with invasive fungal diseases (IFDs) among patients with
haematological disorders in Asia. Eleven institutions from 8
countries/regions participated, with 412 subjects (28.2% possible,
38.3% probable and 33.5% proven IFDs) recruited. The
epidemiology of IFDs in participating institutions was similar to
Western centres, with Aspergillus spp. (65.9%) or Candida spp.
(26.7%) causing the majority of probable and proven IFDs. The
overall 30-day mortality was 22.1%. Progressive haematological
disorder (odds ratio [OR] 5.192), invasive candidiasis (OR 3.679),
and chronic renal disease (OR 6.677) were independently
associated with mortality.
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E-mail: liyang_hsu@yahoo.comIntroductionInvasive fungal diseases (IFDs) are a major cause of morbidity
and mortality in patients with haematological disorders, espe-
cially in the setting of profound neutropenia and/or haemato-
poietic stem cell transplantation (HSCT) [1–3]. Local fungal
epidemiology should be considered before deciding on anti-
fungal prophylaxis or empirical antifungal therapy. Several large-
scale multicentre haematology registries have shown the pre-
dominance of mold over yeast infections, especially invasive
aspergillosis [4–6]. Underlying haematological disorders and
the type of IFD are important determinants of mortality from
IFDs, which averages 28% [7–9]. There are, however, few at-
tempts to document the epidemiology of IFD and its associated
mortality in the Asia-Paciﬁc region [10].Materials and methodsWe performed a 2-year multicentre prospective cohort study
from June 2012, recruiting consecutive adult patients with
haematological disorders who fulﬁlled European Organization
for Research and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy and
Infectious Diseases Mycoses Study Group (EORTC-MSG) deﬁ-
nitions for possible, probable or proven IFD [11], treated at 11
participating centres from 8 regions in Asia (Table 1). The only
individual outcome data collected were 30-day mortality from
the diagnosis of IFD. Institutional data concerning availability of
institutional protocols governing antifungal prophylaxis, number
of patients treated for leukaemia or receiving HSCT, and num-
ber of patients diagnosed with IFD were obtained where avail-
able. One centre (National Taiwan University Hospital)
recruited subjects only for the ﬁrst year of the study. The ethics
review boards of all participating institutions approved the study,Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 1. Participating institutes and types of invasive fungal diseases observed
Institute
Region/
country
Number of
cases recruited
Type of invasive fungal disease Type of fungus
Possible (%) Probable (%) Proven (%)
Candida
spp. (%)
Aspergillus
spp. (%) Others (%)
Queen Mary Hospital Hong Kong 31 11 (35.5) 7 (22.6) 13 (41.9) 7 (35.0) 7 (35.0) 6 (30.0)*
Maedanta Medicity Gurgaon India 16 5 (31.3) 11 (68.8) 0 (0) 0 11 (100) 0 (0)
Rajiv Gandhi Cancer Institute India 46 11 (23.9) 28 (60.9) 7 (15.2) 4 (11.4) 30 (85.7) 1 (2.9) †
Seoul St. Mary’s Hospital South Korea 111 2 (1.8) 73 (65.8) 36 (32.4) 13 (11.9) 91 (83.5) 5 (4.6)‡
National Kidney and
Transplant Institute
Philippines 4 0 (0) 2 (50.0) 2 (50.0) 0 (0) 2 (50.0) 2 (50.0) §
National University Hospital Singapore 15 1 (6.7) 5 (33.3) 9 (60.0) 7 (50.0) 7 (50.0) 0 (0)
Singapore General Hospital Singapore 37 3 (8.1) 11 (29.7) 23 (62.2) 11 (32.3) 21 (67.8) 2 (5.9)ǁ
China Medical University
Hospital
Taiwan 61 36 (59.0) 17 (27.9) 8 (13.1) 1 (4.0) 20 (80) 4 (16.0) ¶
National Taiwan University
Hospital**
Taiwan 12 7 (58.3) 4 (33.3) 1 (8.3) 1 (20.0) 4 (80.0) 0 (0)
Maharaj Nakorn Chiang Mai
Hospital
Thailand 33 30 (90.9) 0 (0) 3 (9.1) 0 (0) 1 (50.0) 2 (66.7)#
National Institute of
Hematology and Blood
Transfusion
Vietnam 46 10 (21.7) 0 (0) 36 (78.3) 35 (97.2) 1 (2.8) 0 (0)
*Four cases of Cryptococcus neoformans, one case of Pencillium marneffei.
†One case of mucormycosis.
‡One case of mucormycosis, three cases of fusariosis, one case of Trichosporon asahii.
§Two cases of mucormycosis.
ǁOne case of Fusarium solani.
¶Two cases of mucormycosis, one case of Trichosporon asahii.
#One case of Cryptococcus neoformans, one case of Trichosporon spp.
**This institute provided data for only 1 year.
CMI Hsu et al. Invasive fungal disease in hematology patients, Asia-Paciﬁc 594.e8and informed consent was obtained from all subjects prior to
recruitment. A detailed description of the methodology is pro-
vided in the Supplementary Data ﬁle.ResultsFour hundred and twelve subjects (28.2% possible IFDs, 38.3%
probable IFDs, and 33.5% proven IFDs) were recruited, with
Aspergillus spp. (65.9%) and Candida spp. (26.7%) forming the
bulk of probable and proven IFDs. The breakdown by subjects
recruited, type of IFD and fungal aetiology according to
participating centre is shown in Table 1. The most common
sites of involvement were lung and bloodstream
(Supplementary Table 1), with the lung also most commonly
involved in possible IFDs (94.8%).
The demographic, clinical and environmental characteristics
of the subjects are shown in Table 2. The majority were male,
had AML, and had received chemotherapy within a month
before developing IFD. At the point of IFD, the majority were
neutropenic, had received antifungal prophylaxis, and were
hospitalized in open general wards. Almost a quarter of cases
had undergone HSCT, the majority being allogeneic HSCT.
Comorbidities were present in a minority of subjects, the most
prevalent being diabetes mellitus (10.2%). Nonstandard anti-
fungal prophylaxis, deﬁned as antifungals that are not recom-
mended in international guidelines for prophylaxis in the
haematology setting [1–3]. in the form of ketoconazole and
nystatin was prescribed to 4.6% of the subjects.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfExcluding HSCT recipients, subjects with AML were more
likely to receive antifungal prophylaxis compared to others
(63.7% vs. 40.9%, p < 0.001). Subjects on nonstandard antifungal
prophylaxis had a higher proportion of invasive candidiasis,
whereas invasive aspergillosis remained the most common
aetiology of IFD for the rest, including subjects who were not
on any prophylaxis (Supplementary Table 2). Voriconazole was
the most common antifungal drug prescribed for treatment of
invasive aspergillosis, whereas amphotericin was most
commonly prescribed for invasive candidiasis (Supplementary
Table 3). For subjects with possible IFD, the majority
received voriconazole (57.8%) and/or amphotericin (43.1%).
The overall 30-day mortality was 22.1%. Univariate analysis of
cohort characteristics showed that progressive haematological
disorder, presence of chronic renal or liver disease, echinocandin
prophylaxis, nonstandard antifungal prophylaxis, proven IFD,
invasive candidiasis, and bloodstream fungal infection were asso-
ciatedwith increasedmortality, whereas pulmonary fungal disease
was associated with a lower risk. On multivariate analysis, pro-
gressive haematological disorder (odds ratio [OR]: 5.192; 95%
conﬁdence interval [CI]: 2.376–11.345; p < 0.001), invasive
candidiasis (OR: 3.679; 95% CI: 1.463–9.250; p < 0.001), and
chronic renal disease (OR: 6.677; 95% CI: 1.481-30.100; p 0.022)
was associated with increasedmortality. TheHosmer-Lemeshow
goodness-of-ﬁt test p value for the multivariate model was 0.140.
Ten of 11 participating centres provided institutional data,
and the proportion of IFDs recruited ranged from 8% to 100%
(median = 78.6%). The number of patients treated at each
institute varied greatly. Most participating centres had antifungalectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 594.e7–594.e11
TABLE 2. Demographic, clinical and environmental characteristics of subjects with IFDs
Characteristic Number of subjects (n [ 412)
Median age (interquartile range), years 49 (37–58)
Male sex (%) 232 (56.3)
Underlying haematological disorder
 AML (%)
201 (48.8)
 ALL (%)
84 (20.4)
 Lymphoma, any (%)
53 (12.9)
 Myelodysplastic syndrome (%)
27 (6.6)
 Myeloma (%)
17 (4.1)
 Aplastic anaemia (%)
14 (3.4)
 Others
16 (3.9)
Chemotherapy
 Received up to 1 month prior to IFD (%)
322 (78.2)
 Induction chemotherapy among subjects with AML or ALL (%)
149 (55.0)
 Consolidation chemotherapy among subjects with AML or ALL (%)
55 (20.3)
Neutropenia at the point of diagnosis of IFD (%) 294 (71.4)
 Profound neutropenia at the point of diagnosis of IFD (%)
189 (64.3)
HSCT prior to IFD (%) 95 (23.1)
 Autologous HSCT (percent of all HSCT)
16 (16.8)
 Allogeneic HSCT (percent of all HSCT)
75 (78.9)
 Cord blood HSCT (percent of all HSCT)
4 (4.2)
Subjects with allogeneic or cord blood HSCT and GVHD at the time
of IFD (percent of all allogeneic or cord blood HSCT)
44 (55.7)
 Acute GVHD (percent of all subjects with GVHD)
24 (54.5)
Other comorbid conditions:
 Diabetes mellitus (%)
42 (10.0)
 Chronic liver disease (%)
39 (9.3)
 Cardiac disease (%)
24 (5.7)
 Chronic renal disease (%)
13 (3.1)
 Solid cancer (%)
10 (2.4)
 Chronic pulmonary disease (%)
10 (2.4)
 Neurological disease (%)
4 (1.0)
Status of haematological disorder at the point of IFD
 Progressive disease (%)
134 (32.5)
 Partial response (%)
40 (9.7)
 Remission (%)
92 (22.3)
 Unknown (%)
146 (35.4)
Receiving antifungal prophylaxis at the point of IFD (%) 239 (58.0)
 Fluconazole (percent of subjects on antifungal prophylaxis)
80 (36.2)
 Itraconazole (percent of subjects on antifungal prophylaxis)
48 (21.7)
 Posaconazole (percent of subjects on antifungal prophylaxis)
38 (17.2)
 Caspofungin (percent of subjects on antifungal prophylaxis)
13 (5.9)
 Micafungin (percent of subjects on antifungal prophylaxis)
13 (5.9)
 Voriconazole (percent of subjects on antifungal prophylaxis)
10 (4.5)
 Amphotericin B deoxycholate (percent of subjects on antifungal prophylaxis)
9 (4.1)
 Liposomal amphotericin (percent of subjects on antifungal prophylaxis)
9 (4.1)
 Nonstandard antifungal prophylaxis (percent of subjects on antifungal prophylaxis)
19 (8.6)
Ward setting at the point of IFD
 Open general ward (%)
195 (47.3)
 High efﬁciency particulate air-ﬁltered room (%)
138 (33.5)
 Isolation room (%)
45 (10.9)
 High dependency/intensive care unit (%)
34 (8.2)
IFD, invasive fungal disease; AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; HSCT, haematopoietic stem cell transplantation; GVHD, graft-vs.-host disease.
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CMI Hsu et al. Invasive fungal disease in hematology patients, Asia-Paciﬁc 594.e10prophylaxis protocols for leukaemia chemotherapy or alloge-
neic HSCT. Galactomannan testing was unavailable in the Thai
and Vietnamese centres, and bronchoalveolar lavage gal-
actomannan testing was available in only four centres
(Supplementary Table 4).DiscussionOur study provided a snapshot of the epidemiology of IFDs in
patients with haematological disorders in Asian institutions.
Although the majority of IFDs occurred in high-risk subjects
[1,2,12], a signiﬁcant minority did not have these risk factors
(146 subjects, 43.8%). Unfortunately, the complete baseline
demographic data were unavailable; hence the actual inci-
dence of IFDs in these non–high-risk groups could not be
determined. However, the results suggest that subjects with
acute lymphoblastic leukaemia might be at a higher risk of
IFDs [12].
The fungal epidemiology was similar to what had been re-
ported from non-Asian centres [4,6,7]. Aspergillus spp. was not
the major fungal pathogen in the Thailand and Vietnam centres,
probably because galactomannan testing was unavailable.
Mucormycosis was rare, even from the Indian centres [10]. The
overall mortality was lower than previous reports [7–9], but
this is likely due to our cut-off of 30 days. The factors inde-
pendently associated with mortality in our cohort are consis-
tent with the published literature [12–16].
The major limitation is that involvement of participating
centres with varied sizes, capabilities and treatment/diagnostic
resources has resulted in the recruitment of a heterogeneous
cohort managed with differing protocols. This complexity has
enhanced the study, but also limits the meaningful conclusions
that can be drawn. In order to facilitate the participation of
centres where resources are limited, the extent of data
collection was restricted. Therefore the rates of IFDs for each
major haematological disorder and the impact of antifungal
therapy on mortality could not be determined.
In conclusion, the epidemiology of IFDs in participating
Asian centres was similar to that in other international cen-
tres, as was the risk of mortality. Further studies to deter-
mine the risk–beneﬁt of antifungal prophylaxis for certain
haematological disorders, especially acute lymphoblastic
leukaemia, are necessary. The heterogeneity of diagnostic,
prophylactic and therapeutic approaches for IFD in the re-
gion highlighted in this study may be a ﬁrst step toward
standardizing such protocols in the future (i.e. better anti-
fungal guidance in the treatment of invasive candidiasis) to
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